Research records indexed for Petrelintide
This page carries 6 of the 8 records that the literature query returned for Petrelintide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 2 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Petrelintide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials pmid:42017294 | 2026 | research-article, Clinical Trial, Phase I | human trial | Not stated | Indexed as research-article, clinical trial, phase i. study model from MeSH "Humans" with publication type "clinical trial, phase i". subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Injections, Subcutaneous; Overweight. |
| Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes pmid:41747885 | 2026 | Review | other | Not stated | Indexed as review. compound named in the abstract, not the title. study model from MeSH "Animals" with no rodent species heading. subject headings: Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Glucagon-Like Peptides; Islet Amyloid Polypeptide. |
| Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials pmid:42452898 | 2026 | research-article, Review | other | Not stated | Indexed as research-article, review. compound named in the abstract, not the title. study model from MeSH "Animals" with no rodent species heading. subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Clinical Trials As Topic; Islet Amyloid Polypeptide. |
| Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs pmid:42586227 | 2026 | Review | other | Not stated | Indexed as review. compound named in the abstract, not the title. study model from MeSH "Animals" with no rodent species heading. subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Islet Amyloid Polypeptide; Amylin Receptor Agonists. |
| Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue pmid:41217931 | 2025 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice". subject headings: Drug Stability; Islet Amyloid Polypeptide. |
| Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment pmid:40608546 | 2025 | Journal Article | rodent | Not stated | Indexed as journal article. compound named in the abstract, not the title. study model from MeSH "Mice". subject headings: Obesity; Receptors, Calcitonin; Anti-Obesity Agents; Structure-Activity Relationship; Drug Discovery. |
Where this page sits
Compound page: Petrelintide. Class: Amylin and amylin receptor agonists.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 172915807, Petrelintide. PubChem, National Library of Medicine (2026). pubchem:172915807
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:petrelintide
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. Journal of medicinal chemistry (2025). pmid:41217931
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes, obesity & metabolism (2026). pmid:42017294
- Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. The lancet. Diabetes & endocrinology (2026). pmid:42810355
- Petrelintide and the evolving role of amylin agonism in obesity. The lancet. Diabetes & endocrinology (2026). pmid:42810353
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.